Cellectar files IND for phase 1 trial of CLR 131 in pediatric cancers
Cellectar Biosciences announces that the company has filed an Investigational New Drug application with the Division of Oncology at the FDA for a proposed Phase 1 study of CLR 131 in children and adolescents with select rare and orphan designated cancers. December 14, 2017